Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) operates as a clinical-stage biopharmaceutical company for developing protein degrader therapeutics to treat disease. The company focuses on the development of small molecule therapeutics that selectively degrade disease-causing proteins, utilizing the body's natural protein degradation system. Kymera primarily caters to the healthcare industry, specifically in the areas of immunology-inflammation and oncology. It was founded in 2016 and is based in Watertown, Massachusetts.

Headquarters Location

200 Arsenal Yards Boulevard, Suite 230

Watertown, Massachusetts, 02472,

United States




Kymera Therapeutics Patents

Kymera Therapeutics has filed 56 patents.

The 3 most popular patent topics include:

  • proteins
  • transcription factors
  • cell biology
patents chart

Application Date

Grant Date


Related Topics




Proteins, Cell biology, Neurotrauma, Heat shock proteins, Transcription factors


Application Date


Grant Date



Related Topics

Proteins, Cell biology, Neurotrauma, Heat shock proteins, Transcription factors



Latest Kymera Therapeutics News

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Dec 8, 2023

Following the dosing of the first patient in Phase II atopic dermatitis trial, Kymera received a $15m milestone payment from Sanofi as part of the global licensing agreement. Share this article The Phase II trials for KT-474 in AD and HS are expected to be completed in Q1 2025. Kymera Therapeutics has dosed the first patient in the Phase II ADVANTA trial evaluating KT-474 in patients with atopic dermatitis (AD). The company received a $15m milestone payment from Sanofi as part of a collaboration ahead of the Phase II trial (NCT06058156) initiation. In 2020, Sanofi signed a global licensing and development agreement with Kymera , as per which the latter received $150m in upfront payments and was entitled to receive over $2bn in milestone payments. Go deeper with GlobalData Kymera received $40m from Sanofi in October, following the start of a Phase II trial (NCT06028230) for KT-474 in patients with hidradenitis suppurativa (HS), a chronic inflammatory skin ailment. The company expects both the AD and HS trials to be completed in Q1 2025, as per a 7 December press release. KT-474 is an interleukin-1 receptor-associated kinase 4 (IRAK-4) protein degrader. It is being developed as a treatment for interleukin 1R (IL-1R) / toll-like receptor (TLR)-driven complex inflammatory diseases. The AD market in the 68 major markets is forecasted to grow from being worth $11.4bn in 2020 to approximately $24.4bn in 2030, as per a GlobalData market analysis report . GlobalData is the parent company of Clinical Trials Arena. How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena. I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the privacy policy Submit and download Phase I HS and AD data The results from the Phase I trial (NCT04772885) of KT-474 in a healthy volunteer cohort showed degradation of IRAK4 in the participant’s blood. A mean reduction of over 93% of IRAK4 was seen at 600mg–1,600mg and a reduction of over 95% was observed after 14 daily doses at 50mg–200mg. The Phase I trial also enrolled 21 patients with either moderate to severe HS or moderate to severe AD in an open-label cohort. A reduction of disease-relevant inflammatory biomarkers was demonstrated in the blood and skin of patients with HS and patients with AD and was associated with improvement in skin lesions and symptoms. The results were also published in the Nature Journal in November. Other protein degraders in Kymera’s pipeline include KT-333 for the treatment of relapsed or refractory lymphomas, large granular lymphocytic leukaemia, and solid tumours and KT-413 for the relapsed and/or refractory B-cell non-Hodgkin’s lymphomas. The positive data from the ongoing Phase I trials for both therapies was reported in June. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Kymera Therapeutics Frequently Asked Questions (FAQ)

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2016.

  • Where is Kymera Therapeutics's headquarters?

    Kymera Therapeutics's headquarters is located at 200 Arsenal Yards Boulevard, Suite 230, Watertown.

  • What is Kymera Therapeutics's latest funding round?

    Kymera Therapeutics's latest funding round is IPO.

  • How much did Kymera Therapeutics raise?

    Kymera Therapeutics raised a total of $197M.

  • Who are the investors of Kymera Therapeutics?

    Investors of Kymera Therapeutics include Redmile Group, Bain Capital, BlackRock, Wellington Management Company, Leukemia & Lymphoma Society and 16 more.

  • Who are Kymera Therapeutics's competitors?

    Competitors of Kymera Therapeutics include Pin Therapeutics and 1 more.


Compare Kymera Therapeutics to Competitors

Amphista Therapeutics Logo
Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics to help harness the body's natural processes to selectively degrade and remove disease-causing proteins. It leverages cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression. The company was founded in 2017 and is based in Cambridge, U.K.

Pin Therapeutics

Pin Therapeutics operates as a pharmaceutical company. It develops therapeutic drugs for chemical biology-driven protein degradation. It provides a screening system for enhancing emotional health (E3) ligases and molecular glue degraders. The company was founded in 2017 and is based in Seongnam-Si, South Korea.


FIMECS operates as a drug discovery biotech firm. It focuses on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company was founded in 2019 and is based in Fujisawa, Japan.

Arvinas Logo

Arvinas is a clinical-stage biotechnology company that focuses on targeted protein degradation therapeutics. The company's main offerings include the development of therapies that uses the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas primarily sells to the healthcare sector, with a particular focus on oncology and neuroscience. It was founded in 2013 and is based in New Haven, Connecticut.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics (NASDAQ: NRIX) discovers drugs to control protein levels. It specializes in ubiquitin E3 ligases, which are key enzymes responsible for protein breakdown in human cells. These drugs are primarily aimed at treating a broad range of diseases, with a particular focus on cancer. It serves the healthcare and pharmaceutical industry. It was founded in 2012 and is based in San Francisco, California.

C4 Therapeutics Logo
C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company. The company's TORPEDO platform develops therapeutic drugs for the treatment of cancer and other diseases. The company was founded in 2016 and is based in Watertown, Massachusetts.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.